PRCT in the 13F filings
Procept Biorobotics Corp · CUSIP 74276L105
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 22 Jan 2026
- Managers listing it
- 24
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 3 listed it in both
- Shares listed
- 13,824,371
- combined, among listed positions
- Reported value
- $435m
- combined, at the quarter end
Among the 92 comparable managers: 17 buyers (opened or added shares) and 10 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -2,468,989.
Managers listing PRCT in Q4 2025
24 of 24 holders
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 340,841 shares now+315,065
- Millennium Management LLCexisting position · 383,137 shares now+278,077
- ExodusPoint Capital Management LPnew position · 237,198 shares now+237,198
- Squarepoint Ops LLCnew position · 191,581 shares now+191,581
- Baillie Gifford & Coexisting position · 1,015,978 shares now+157,147
Reductions
- Fidelity (FMR LLC)existing position · 4,653,111 shares now-3,382,944
- T. Rowe Price Associates Incexisting position · 705,740 shares now-169,441
- Marshall Wace LLPexisting position · 217,442 shares now-164,092
- AllianceBernstein LPexisting position · 3,385,422 shares now-34,362
- Verition Fund Management LLCexisting position · 34,800 shares now-26,993
New positions and exits
New (4)
Exited (3)
- Wellington Management Group LLPwas $16m
- Freestone Grove Partners LPwas $483k
- Walleye Capital LLCwas $56k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2021 | 4 | $191m | n.a. | n.a. |
| Q4 2021 | 3 | $124m | n.a. | n.a. |
| Q1 2022 | 2 | $128m | n.a. | n.a. |
| Q2 2022 | 2 | $51m | n.a. | n.a. |
| Q3 2022 | 1 | $16k | n.a. | n.a. |
| Q4 2022 | 2 | $768k | n.a. | n.a. |
| Q1 2023 | 3 | $11m | n.a. | n.a. |
| Q2 2023 | 1 | $1.8m | n.a. | n.a. |
| Q3 2023 | 1 | $1.4m | n.a. | n.a. |
| Q4 2023 | 3 | $103m | 2 | 1 |
| Q1 2024 | 5 | $129m | 2 | 2 |
| Q2 2024 | 6 | $610m | 4 | 2 |
| Q3 2024 | 5 | $768m | 1 | 4 |
| Q4 2024 | 9 | $1.0bn | 8 | 1 |
| Q1 2025 | 6 | $718m | 5 | 1 |
| Q2 2025 | 3 | $232m | 3 | 0 |
| Q3 2025 | 3 | $201m | 2 | 1 |
| Q4 2025 | 4 | $194m | 17 | 10 |
| Q1 2026 | 3 | $56m | 13 | 15 |
| Q2 2026 | 2 | $36m | 15 | 12 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
PRCT and LLY →PRCT and JNJ →PRCT and VRTX →Choose a stock to compare with PRCT →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own PRCT, latest filings →Back to the 13F Explorer →